SHARE is proud to collaborate with the PAN Foundation, an independent, national 501 (c)(3) organization dedicated to helping federally and commercially insured people living with life-threatening, chronic and rare diseases with the out-of-pocket costs for their prescribed medications.
January 2019 Resource Roundup
Welcome to our new, monthly resource roundup! Each month, we’ll be curating study opportunities, new clinical trials, research results, news articles, personal perspectives, and upcoming events of interest to women and families affected by breast, ovarian, or metastatic breast cancer.
Giving Tuesday 2018: How do you SHARE?
#GivingTuesday is a global day of giving that harnesses the collective power of individuals, communities and organizations to encourage philanthropy and celebrate generosity worldwide, taking place this year on November 27. SHARE is excited to be joining with other organizations worldwide as we take part to bring attention to women affected by breast or ovarian cancer.
September is Ovarian Cancer Awareness Month!
Join SHARE in spreading what real survivors wish people knew about ovarian cancer during ovarian cancer awareness month 2018!
The American Cancer Society estimates one in 78 women will be diagnosed with ovarian cancer in their lifetime.
We Run For Hope 2018
Runners and walkers from around the city gathered at Flushing Meadows Park on Sunday, June 4, for the We Run for Hope 5K/10K Run and Walk. This event, held annually on National Cancer Survivors Day, is a great opportunity to support women with breast or ovarian cancer while also staying fit and active.
FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy as a Treatment for Women with Advanced Ovarian Cancer Following Initial Surgery
Avastin is now approved for ten distinct uses across six different types of cancer in the United States.
SOUTH SAN FRANCISCO, Calif. – June 13, 2018 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin® (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin as a single agent, for the treatment of women with advanced (stage III or IV) ovarian cancer following initial surgical resection.
10 Years Later: An ovarian cancer survivor looks back at attending SGO for the first time (Part 2)
By Annie Ellis
Last month I attended the 2018 annual meeting of the Society of Gynecologic Oncology (SGO). I was a bit sentimental because it was the 10th anniversary of attending for the first time as part of SHARE's 2008 Survivorship Presentation.
What a difference 10 years makes! In 2008 I walked in practically bald and wearing teal from head to toe.
May 8 is World Ovarian Cancer Day!
On May 8, people around the world are gathering to support awareness of ovarian cancer. Join SHARE by following us on Facebook, Twitter, and Instagram, where we’ll be posting about signs, symptoms, and stories you can share with the women in your life.
Honoring Martha Solonche, Pioneer of SHARE’s Ovarian Program
SHARE is saddened by the recent death of Martha Solonche, a pioneer of our ovarian program.
SHARE’s Annual Volunteer Party
April is National Volunteer Appreciation Month, and SHARE hosted its annual volunteer party to show how much we appreciate the incredible commitment of our volunteers. It was another great gathering with a raffle, food, music, and of course, amazing company.
